

TVM UK to become DÔMES PHARMA

Kirtlington, July 4th 2024 –**Founded in the UK in 2016, TVM UK is adopting the name of its parent company, Dômes Pharma.** It is a part of the company strategy to group all of its innovative and focused activities under the same Dômes Pharma name in all countries. Located in Kirtlington (Oxfordshire), the UK team comprises 20 people, including 10 field sales representatives.

Jonathan Hill (UK Country Manager) says: *“I’m delighted to announce that TVM UK is changing its name to Dômes Pharma. This will align with the other operating companies within the group. TVM UK has always been owned by the Dômes Pharma group, and since the start of our journey in the UK market we have been synonymous with expertise & outstanding levels of customer service in selected speciality segments of the animal health market and this won’t change.”*

Since 1982, Dômes Pharma has been committed to developing solutions in specialised therapeutic areas for the health and well-being of pets, including ophthalmology, neurology and poisoning management. The group made a name for itself in the UK market with its Anti-Tox range, driven by a mission to make the treatment of poisons as simple as possible, whilst striving to raise awareness of potential dangers and therefore significantly increasing the number of cases handled.

The group's historic expertise also incorporates epilepsy, behaviour, and the ophthalmic range - which is experiencing the greatest growth due to the arrival of 3 new products: OphtaPRIME, Remend® BioHAnce™ Corneal Gel and Remend® BioHAnce™ Dry Eye Lubricant Drops. Dômes Pharma also focuses on driving innovation in specialised areas – with DogStem®, the first and only licensed stem cell treatment for dogs with mild to severe osteoarthritis in elbow and hip joints¹, as a relatively recent addition to the portfolio.

Hill continues: *“Under the Dômes Pharma name we will continue to build and grow on this very strong foundation. I’m looking forward to working with the entire Dômes Pharma team as we increase our presence as a leading specialty pharmaceutical company, bringing our ethos to new speciality segments with innovative products and solutions for vets in the UK. Dômes Pharma remains a family-owned business, and the culture of the company really reflects this and we live by our values of kindness, boldness and responsibility.”*

Beyond its products, Dômes Pharma aims to support the daily practice of veterinarians through an integrated approach: provision of important products and creation of educational support materials. To mark our rebranding, we have interviewed vets and nurses to discover more about their vision of the profession, what drives them, and the challenges they face. We also interviewed Dômes Pharma employees, who are committed to improving the health and well-being of our pets. The video testimonials can be found at <https://www.tvm-uk.com/domespharma/>

1. Dogstem SPC

®Remend is a registered trademark of SentrX , OphtaPRIME is a registered trademark of Dômes Pharma.
Dogstem is a registered trademark of Equicord

ENDS

Contact

Jonathan Hill, Country manager: | j.hill@domespharma.com

Corporate Communication team | communication@domespharma.com | help@tvm-uk.com

Dômes Pharma is the trading name of TVM UK Animal Health Ltd, Kirtlington Business Centre, Slade Farm, Kirtlington, Oxfordshire, UK. OX5 3JA. Company registration number: 10041959

About Dômes Pharma

Dômes Pharma, an independent family-owned group, a pioneer in animal health, has been developing, manufacturing and marketing solutions for the health and well-being of pets since 1947. Established in Auvergne in central France, the region of volcanoes and its domes from which it takes its name, in 2016 the Group began its international expansion by opening subsidiaries in the UK, Germany, Spain and the USA. In July 2023, the Group acquired the American company SentrX Animal Care based in Salt Lake City (Utah), which develops and manufactures ophthalmology products, based on an exclusive patented technology that potentiates the action of Hyaluronic acid on the eye of animals. With this acquisition, Dômes Pharma strengthens its world leadership in veterinary ophthalmology while creating a launch pad for its range of therapeutic specialities in North America.